Executive Summary
The under-60 TAVR case just got harder to defend: a JTCVS Open analysis of ~10,000 propensity-matched patients shows 5-year mortality of 18.3% with TAVR versus 11.3% with SAVR, alongside higher rates of pacemaker, paravalvular leak, and reintervention on the transcatheter side. A JACC report from PREVUE-VALVE simultaneously exposes how AI-ECG structural heart screening loses discrimination when moved from hospital cohorts (AUC 0.83) into community-dwellers (AUC 0.71), a caution flag on the aortic stenosis screening enthusiasm curve. Meanwhile a 48,565-patient German registry in BMC Cardiovascular Disorders found self-expanding TAVR valves associated with lower in-hospital mortality but higher stroke and pacemaker risk versus balloon-expandable — hypothesis-generating, not device-selecting. Together the day tightens the case that valve choice, patient age, and CT-based lifetime planning remain the decisive variables — not the delivery route.
- SAVR beat TAVR at 5 years for mortality (11.3% vs 18.3%) in propensity-matched patients under 60, reinforcing ACC/AHA and ESC age-threshold guidance (JTCVS Open).
- Self-expanding TAVR carried 15% lower in-hospital mortality but 35% higher stroke risk vs balloon-expandable across 48,565 German cases (BMC Cardiovasc Disord).
- AI-ECG structural heart detection dropped from AUC 0.83 in hospitals to 0.71 in community patients, driven by milder disease spectrum (JACC).
- Post-TAVR VExUS ≥2 predicted acute kidney injury with 100% sensitivity and 88% specificity in a 101-patient cohort, though small and retrospective (J Cardiothorac Vasc Anesth).
- Only 7.0% of structural heart trial oversight committee seats since 2010 have gone to women, with no meaningful improvement over 15 years (JACC Advances via TCTMD).
What to watch: Medtronic's September 1 earnings will bring first commentary on Evolut low-risk 10-year data and TTVR pipeline momentum against Edwards' EVOQUE real-world traction.
Aortic Valve (TAVR/TAVI)
The under-60 SAVR-vs-TAVR question is no longer close. The Tulane TriNetX analysis in JTCVS Open (retrospective, propensity-matched, N=1,666 per arm, patients <60y treated 2006-2025) found 5-year mortality of 11.3% for SAVR vs 18.3% for TAVR, with TAVR also linked to higher AMI, endocarditis, complete AV block, pacemaker, paravalvular leak, and reintervention. This aligns squarely with ACC/AHA 2020 Class I SAVR under age 65 and ESC 2025 Class I SAVR under 70 — but a growing minority of younger patients continue to receive TAVR against guideline direction, and this dataset shows the durability tax. [NOTABLE] A separate 48,565-patient German DESTATIS registry in BMC Cardiovasc Disorders comparing balloon-expandable to self-expanding transfemoral TAVR found SE associated with lower adjusted in-hospital mortality (RR 0.85) and major bleeding (RR 0.78) but higher stroke (RR 1.35) and pacemaker (RR 1.09); the authors label the findings hypothesis-generating given confounding by anatomy. Meanwhile a Structural Heart perspective reinforces the ESC 2025 emphasis on CT-based lifetime planning at the index procedure — coronary access preservation and future TAV-in-TAV feasibility must be modeled before the first valve, not after. TCTMD/Medical Dialogues also flagged 10-year TAVR outcomes showing higher risk with older-generation valves — a reminder that pooled long-term TAVR safety data still lean heavily on devices no longer in use.
Mitral Valve (MitraClip, PASCAL, TMVR)
Transfemoral TMVR posted a real-world win. Cardiovascular Business coverage reports positive outcomes for high-risk patients undergoing transfemoral TMVR, coinciding with the first commercial Pennsylvania TMVR case. Set against this, a JACC Advances analysis by Zuin et al. re-examined the robustness of TEER trial evidence in functional MR — the exact question that produced the ESC 2025 upgrade to Class I based on COAPT, RESHAPE-HF2, and meta-analysis. ACC/AHA 2020 still holds TEER in ventricular SMR at Class IIa, and the persistence of scrutiny in JACC-family journals suggests the transatlantic gap won't close casually. On the atrial functional MR front, a new OCEAN-Mitral/REVEAL-AFMR propensity analysis from reference literature earlier this cycle showed TEER associated with lower mortality/HF hospitalization (HR 0.65) vs medical therapy — supporting the ESC 2025 formal recognition of atrial SMR as a distinct entity requiring its own pathway. A first-in-human trial of the Vesalius TMVr System (N=5) began recruiting, adding to the crowded degenerative MR repair pipeline where surgical repair remains the ACC/AHA and ESC Class I standard when durable results are expected.
Tricuspid Valve (TriClip, TTVR)
The tricuspid workflow is going robotic. A preclinical framework in IEEE Trans Biomed Eng validated an autonomous CT-derived path planning and Jacobian-controlled catheter navigation system for TTVI across 15 real patient datasets and three phantoms, achieving millimeter-scale tracking. Clinically premature, but a signal about where operator workload reduction is heading given the anatomic complexity that limits current TTVI scalability. ESC 2025 rates transcatheter tricuspid treatment Class IIa (LOE A) for high-risk symptomatic severe TR, based on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II — while ACC/AHA 2020 does not address transcatheter TR therapy at all, a gap the next US update will need to close. Recent STS/ACC TVT Registry real-world EVOQUE data (98.4% procedural success, 3.1% 30-day mortality, 15.9% new CIED) referenced in our knowledge base continues to reinforce the ESC direction while highlighting the pacemaker burden that surgical TR repair does not carry. Surgical TR referral timing remains the persistent unresolved issue — both guidelines agree patients arrive too late.
Surgical vs. Transcatheter Comparisons
Two datasets today sharpen the surgical-transcatheter divide. The JTCVS Open under-60 SAVR-vs-TAVR analysis confirms the guideline-preferred pathway with hard 5-year outcomes: SAVR mortality 11.3% vs TAVR 18.3%, plus lower pacemaker, PVL, and reintervention rates surgically. Separately, a Cardiovascular Revascularization Medicine analysis of 158 patients undergoing aortic root replacement for acute type A dissection (retrospective, single-institution) found bioprosthetic valve use independently associated with 3.23-fold higher long-term mortality vs mechanical valves — despite equivalent 30-day mortality. Age was substantially different between groups (65.3 vs 51.6y), so residual confounding is a real concern, but the finding challenges the reflexive drift toward biological valves in younger dissection patients driven by future TAVI-in-SAV planning. A separate long-term outcomes analysis from reference literature previously showed mechanical valves outperformed bioprostheses in the 50-70 age range, with 19mm biological valves the worst-performing subgroup. Bottom line: the "biological valve first, TAVI-in-SAV later" strategy for younger patients still lacks the long-term data to displace mechanical valves. Guidelines have not moved on this.
Device & Technology
AI screening for aortic stenosis remains a real opportunity but the community-deployment challenge just got quantified. The EchoNext AI-ECG model in PREVUE-VALVE (JACC, N=2,402 community-dwelling) saw AUC drop from 0.83 in hospital-derivation cohorts to 0.71 in the community, driven by lower disease prevalence (8% vs 43%) and milder phenotypes. This is the fundamental spectrum-bias problem for opportunistic screening and mirrors the concurrent Cardiovascular Business coverage of AI-powered opportunistic AS screening enthusiasm — the tools work best where disease is already dense, which is precisely not where screening delivers most value. On imaging-guided procedural planning, a two-center retrospective study (N=101) showed post-TAVR VExUS ≥2 predicted AKI with 100% sensitivity and 88% specificity (AUC 0.97), a striking discriminator that warrants prospective replication before adoption. A JACC case report also describes snare-assisted transseptal antegrade TAVR — a niche bail-out technique but a reminder that the transfemoral highway isn't always open.
Industry & Market
Medtronic faces a potential injunction in the ongoing Applied Medical patent case, a headline overhang heading into September 1 earnings. Edwards Lifesciences continues to attract institutional inflows — Mitsubishi UFJ took a $126M position and BlackRock added new stake, reflecting continued conviction on the tricuspid EVOQUE ramp. Boston Scientific Q2 2026 earnings beat on margins and EPS but the stock remains near six-month lows.
Financial Analysis
The market divergence between Edwards (+15.7% over 6 months) and Boston Scientific (-30.3%) tells the structural heart story in miniature. Edwards' EVOQUE tricuspid platform is landing during the exact window the ESC 2025 guidelines moved transcatheter TR to Class IIa, and real-world STS/ACC TVT Registry data (referenced in our knowledge base) confirmed 98% procedural success — the clinical story matches the tape. Medtronic (-1.1% over 6 months) is stuck in a story-vacuum period ahead of its September 1 earnings, with the Applied Medical injunction adding litigation risk. The under-60 SAVR win in JTCVS Open cuts both ways for Edwards and Medtronic: it validates SAVR volumes (INSPIRIS, Avalus) but constrains the low-risk TAVR growth narrative that has driven multi-year multiple expansion. Anteris Technologies (+68% over 6 months) reflects the smaller-cap valve development enthusiasm that runs on pipeline events rather than earnings; the DurAVR TAVR platform remains investigational.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $92.28 (+1.43%), 6-month +15.67%
- Market cap $53.2B; trailing P/E 53.96, forward P/E 27.34; beta 0.85; 52-week range $72.30-$96.29
- Analyst target $100.96 (26 analysts, range $84-$110), consensus Buy
- Next earnings October 29; EPS estimate $0.74, revenue estimate $1.68B
- Institutional flows accelerating (Mitsubishi UFJ $126M position, BlackRock new stake, Danske Bank 524K shares) reflect confidence in the EVOQUE tricuspid ramp against ESC 2025 Class IIa tailwind. SAPIEN low-risk narrative complicated by today's JTCVS under-60 SAVR advantage.
Medtronic (MDT)
- Close: $94.13 (+2.22%), 6-month -1.14%
- Market cap $120.5B; trailing P/E 25.24, forward P/E 14.68; beta 0.57; 52-week range $73.31-$106.33
- Analyst target $98.44 (25 analysts, range $78-$121), consensus Buy
- Next earnings September 1; EPS estimate $1.39, revenue estimate $9.55B
- Applied Medical injunction risk overhangs near-term. Evolut Low Risk 10-year data expected to shape the Q2 call narrative, along with any TTVR pipeline update as Edwards' EVOQUE builds a lead.
Abbott (ABT)
- Close: $114.43 (+1.55%), 6-month +3.35%
- Market cap $198.0B; trailing P/E 36.44, forward P/E 18.87; beta 0.58; 52-week range $81.97-$137.49
- Analyst target $119.40 (25 analysts, range $103-$135), consensus Buy
- Next earnings October 14; EPS estimate $1.42, revenue estimate $12.99B
- MitraClip franchise cushioned by ESC 2025 Class I upgrade for ventricular SMR, though ACC/AHA remains at IIa. TriClip continues to compete in the TR space where clinical evidence favors TEER for repair-suitable anatomy.
Boston Scientific (BSX)
- Close: $52.01 (+3.05%), 6-month -30.26%
- Market cap $75.4B; trailing P/E 20.48, forward P/E 15.13; beta 0.57; 52-week range $42.20-$109.50
- Analyst target $62.69 (29 analysts, range $44-$94), consensus Buy
- Next earnings October 28; EPS estimate $0.81, revenue estimate $5.26B
- Q2 2026 margins and EPS beat guidance but the six-month drawdown reflects broader growth-multiple compression rather than a valve-specific issue. ACURATE and Sentinel positioning remain areas to watch.
Anteris Technologies (AVR.AX)
- Close: A$13.50 (+2.04%), 6-month +68.33%
- Market cap A$1.3B; forward P/E negative (pre-revenue); 52-week range A$5.20-A$15.47
- Analyst target A$13.00 (single analyst), consensus Hold
- DurAVR biomimetic TAVR remains investigational. The 6-month rally sits on pipeline optimism rather than pivotal readouts.
Market outlook: The divergence between transcatheter incumbents (Edwards outperforming) and diversified med-tech (Boston Scientific and Medtronic lagging) reflects a market pricing structural heart momentum specifically, not medical device broadly. The tricuspid category — Class IIa in ESC 2025, still absent from ACC/AHA 2020 — is the current growth vector, and today's SAVR-under-60 data validates that low-risk TAVR expansion carries durability risk not yet fully priced into forward multiples.
Clinical Trial Updates
Aortic
- [LANDMARK] NCT05261204 — Transcatheter Aortic Valve Implantation Versus Standard Surgical Aortic Valve Replacement. Status: Active, not recruiting. Enrollment: 4,000. Sponsor: Centre Cardiologique du Nord. Interventions: TAVI vs bioprosthesis vs sutureless. A large three-arm surgical-transcatheter comparison whose readout will inform how sutureless SAVR competes in the space TAVR has been claiming.
Mitral Repair
- NCT07470788 — FIH ITA Study, Vesalius TMVr System for Symptomatic Degenerative Mitral Regurgitation. Status: Recruiting. Enrollment: 5. Sponsor: Vesalius Cardiovascular. First-in-human data on a new degenerative MR repair platform in a crowded field where surgical repair remains Class I in both guidelines.
Landmark trials to watch across the field include EARLY TAVR (asymptomatic severe AS, informing ESC 2025 IIa early intervention), TRILUMINATE Pivotal and TRISCEND II (tricuspid, powering ESC 2025 Class IIa), COAPT and RESHAPE-HF2 (functional MR, driving ESC Class I TEER), and PARTNER 3 / Evolut Low Risk long-term follow-up (which will define the next ACC/AHA update's TAVR age threshold decision).
Social & Conference Highlights
Only 7.0% of structural heart trial oversight committee seats since 2010 have gone to women, per a JACC Advances systematic review of 88 high-impact trials — a proportion that has not budged over 15 years despite dramatic technology and guideline evolution. Only 12% of committees have a woman as chair; 14% of senior authorships. The aortic space is the worst (4.9%), mitral the least-bad (14.5%). Mayra Guerrero (Mayo) and Harriette Van Spall (McMaster) frame the fix in structural terms: protected time and salary support for female investigators, deliberate committee-seat invitations by industry and academic sponsors, and mentorship at the institutional level. The observation that only 3.1% of TAVI operators are women bounds the near-term ceiling, but as Van Spall notes, principal investigators do not require operator status — the leadership gap is a research-training and dedicated-time gap, not a procedural-volume gap.
Forward look: Medtronic's September 1 earnings will set the tone on Evolut long-term durability commentary and whether the low-risk TAVR narrative can sustain against today's under-60 SAVR data. Watch for how the next ACC/AHA valve guideline update — anticipated in coming cycles — reconciles the growing evidence base against the ESC 2025 leap: TAVI age threshold at 70, TEER Class I for ventricular SMR, transcatheter tricuspid Class IIa, and formal recognition of atrial secondary MR.